Ana Martinez – författare

The Drug Discovery Series covers all aspects of drug discovery and medicinal chemistry and contains over 70 books published since 2010. Providing comprehensive coverage of this important and far-reaching area, the books encourage learning in a range of different topics and provide valuable reference sources for scientists working outside their areas of expertise. Books feature case studies to bring different aspects of the drug discovery process alive and they detail the fundamental science necessary for understanding through to the most up-to-date discoveries and cutting edge technologies. Chapters are written and edited by experienced researchers from both industry and academia. This series will be of particular interest to postgraduate students and medicinal chemists and biochemists working in academia or industry.

The Drug Discovery Series covers all aspects of drug discovery and medicinal chemistry and contains over 70 books published since 2010. Providing comprehensive coverage of this important and far-reaching area, the books encourage learning in a range of different topics and provide valuable reference sources for scientists working outside their areas of expertise. Books feature case studies to bring different aspects of the drug discovery process alive and they detail the fundamental science necessary for understanding through to the most up-to-date discoveries and cutting edge technologies. Chapters are written and edited by experienced researchers from both industry and academia. This series will be of particular interest to postgraduate students and medicinal chemists and biochemists working in academia or industry.

Alzheimer''s disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease''s progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective intervention for Alzheimer''s disease.

Emerging Drugs and Targets for Alzheimer''s Disease collects some of the most outstanding examples of new drugs currently under pharmaceutical development or new targets in the validation process that will reach the Alzheimer''s drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts, these volumes are an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the neurosciences field.

Alzheimer''s disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease''s progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective intervention for Alzheimer''s disease.

Emerging Drugs and Targets for Alzheimer''s Disease collects some of the most outstanding examples of new drugs currently under pharmaceutical development or new targets in the validation process that will reach the Alzheimer''s drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts, these volumes are an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the neurosciences field.

Affecting over 1.5 million people across the world, Parkinson''s disease is a progressive neurological condition characterized, in part, by the loss of dopaminergic neurons in the substantia nigra pars compacta. It affects 1.5% of the global population over 65 years of age. As life expectancy is increasing, over the next few years the number of patients with Parkinson´s disease will grow exponentially. To date, there are no available treatments that are capable of curing Parkinson´s disease, and the current goal of therapy, dopamine replacement strategies, is to reduce symptoms. After several years of disease progression, treatment is complicated by the onset of motor fluctuations and dyskinesias. This information reveals the great importance and social need of finding an effective therapeutic intervention for Parkinson´s disease.

This exemplary new book reviews some of the most outstanding examples of new drugs currently in pharmaceutical development or new targets currently undergoing the validation process to try to reach the Parkinson´s drug market in the next few years as potential disease modifying drugs. Providing up to date and comprehensive coverage, this book is essential reading for researchers working in academia and industry in any aspect of medicinal chemistry or drug discovery.